Genomics company Illumina Q3 revenue beats expectations, helped by clinical market growth

Illumina

30/10/2025 20:14

Overview

Illumina Q3 revenue of $1.08 bln beats analyst expectations

Adjusted EPS of $1.34 for Q3 beats consensus estimates

Company repurchased 1.2 mln shares for $120 mln

Outlook

Company expects FY25 constant currency revenue decline of (1.5%) to (0.5%)

Illumina raises FY25 non-GAAP EPS guidance to $4.65 - $4.75

Company anticipates FY25 non-GAAP operating margin of 22.75% to 23%

Result Drivers

CLINICAL MARKET GROWTH - Revenue acceleration driven by growth in clinical market, Illumina's largest segment, per CEO Jacob Thaysen

EX-CHINA GROWTH - Company returned to growth outside of China, executing on strategic pillars for long-term targets

NEW TECHNOLOGIES - Launched 5-base solution and Constellation mapped read technology, enhancing genomic insights

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$1.08 bln
$1.07 bln (16 Analysts)
Q3 Adjusted EPS
Beat
$1.34
$1.16 (18 Analysts)
Q3 EPS
$0.98
Q3 Adjusted Net Income
Beat
$206 mln
$181.62 mln (16 Analysts)
Q3 Net Income
$150 mln
Q3 Gross Margin
67.6%
Q3 Adjusted EBIT Margin
24.5%
Q3 Adjusted Gross Margin
69.2%
Q3 EBIT Margin
21%


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy", 11 "hold" and 3 "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Illumina Inc is $110.00, about 13.6% above its October 29 closing price of $95.03

Press Release: ID:nPn2khdXja

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)